Description
Product details
Eligolux 150 delivers 150mg of elagolix per tablet, formulated as an oral, once-daily option in convenient packs for ongoing therapy. As a non-peptide GnRH receptor antagonist, it selectively suppresses pituitary gonadotropins, reducing ovarian estrogen production without the flare effect of agonists. Ideal for patients with milder symptoms or those prioritizing bone health, this dose minimizes hypoestrogenic risks while targeting endometriotic pain. Take Eligolux 150 whole with water, with or without food, preferably at the same time daily. Storage requires a cool, dry environment below 30°C, away from children and moisture. Steris Healthcare ensures GMP-compliant manufacturing, making it accessible across India for endometriosis care. Primary Uses and Indications Eligolux 150 primarily treats moderate endometriosis-associated pain, including dysmenorrhea, chronic pelvic discomfort, and dyspareunia. Endometriosis impacts 10% of reproductive-age women, causing ectopic endometrial growth that triggers inflammation and scarring; elagolix 150mg curbs estrogen-driven progression. Prescribed when NSAIDs or combined pills prove inadequate, it excels in non-severe cases, allowing prolonged use. Emerging evidence supports its role in heavy menstrual bleeding from fibroids, though primary approval focuses on pain relief. Start therapy within the first week of menses for optimal synchronization. Mechanism of Action Elagolix in Eligolux 150 competitively binds GnRH receptors, dose-dependently inhibiting LH/FSH release. This lowers estradiol by 40-60%—less aggressive than 200mg—halting endometrial tissue proliferation outside the uterus. Peak levels hit in 1 hour, with a 4-6 hour half-life supporting steady-state suppression on QD dosing. Unlike agonists, no initial hormone surge occurs, preventing worsened pain. Partial estrogen reduction preserves some bone-protective effects, differentiating it from deeper suppression therapies. Key Benefits Eligolux 150 shines in clinical responsiveness: phase 3 trials showed 32% dysmenorrhea resolution versus 20% placebo at 6 months, with 50% pain score drops. Quality-of-life gains include better work attendance, sleep, and relationships, per EQ-5D assessments. Extended 24-month approval suits long-term control, with amenorrhea in 40-50% of users reducing bleeding volume by 70%. Oral ease beats injectables, enhancing adherence at 85% in studies. Lower BMD impact (0.5-1% loss/year) allows safer continuation versus higher doses. Benefit Trial Data Patient Impact Pain Reduction 32-50% dysmenorrhea-free Daily activity restoration Bleeding Control 70% volume drop Anemia prevention Long-Term Use: Up to 24 months Sustained relief QoL Improvement EQ-5D gains Emotional well-being Potential Side Effects Vasomotor symptoms dominate: hot flashes (20-30%), headaches (17%), and night sweats (10-15%) emerge early but fade. Nausea (8%), insomnia (7%), and mild depression (5%) affect minorities, with a 70% event rate mostly grade 1. BMD decline averages -0.9% at the spine after 12 months, monitored via DEXA. Discontinuation hovers at 5-8%. Side Effect Incidence Mitigation Hot Flashes 20-30% Ventilation, timing Headache 17% Analgesics BMD Loss 0.9% Supplements, scans Mood Shifts 5% Monitoring Serious Risks and Management Suicidality (0.1-0.5%) demands baseline psych screening; halt if worsening. Liver enzymes rise in 1%, requiring LFTs at 3/6 months. Rare anaphylaxis or thromboembolism prompts immediate cessation. Avoid in osteoporosis or smokers >35. Dosage Guidelines 150 mg once daily for up to 24 months in normal/mild liver function; limit to 6 months in moderate impairment (Child-Pugh B). No titration needed; miss a dose? Resume the next day, no doubling. Pair with 1 g calcium/800 IU vitamin D daily. Precautions and Contraindications Pregnancy category X: mandates non-hormonal birth control during and 1 week post-therapy. Screen hepatic/renal function; avoid severe cases. CYP3A interactions (e.g., rifampin reduces efficacy) need dose review. Breastfeeding is contraindicated. Clinical Evidence and Efficacy Elaris trials (n=1,689) confirmed superiority: co-primary endpoints met with 75% responder rates for pain. 12-month extensions showed persistent efficacy and low rebound. Versus 200mg, 150mg balances tolerability for moderate pain. Conclusion Eligolux 150 empowers women with moderate endometriosis pain through precise, extended hormonal modulation and proven outcomes. Regular physician oversight maximizes safety and efficacy.
